Women's Health

GLP-1 and Fertility: What Women and Men Need to Know

GLP-1 Companion · 8 min read

When GLP-1 medications became widely prescribed, the discussion centered on weight loss and blood sugar. Fertility was not part of the standard counseling conversation. Then, starting in 2023, a pattern emerged in online communities and physicians' offices: women who had struggled to conceive were getting pregnant unexpectedly while on GLP-1 medications. The anecdotal reports accumulated quickly enough that media and medical journals took notice, coining the phrase 'Ozempic baby boom.' This is not a coincidence or a mystery — it is a predictable consequence of how these medications affect metabolism and reproductive hormones. Understanding it is essential for anyone on a GLP-1 medication in their reproductive years.

How GLP-1 Medications Restore Ovulation in Women

Ovulation is regulated by the hypothalamic-pituitary-ovarian (HPO) axis. In women with obesity or insulin resistance, several interconnected mechanisms disrupt this axis and suppress ovulation:

1. Insulin resistance and hyperinsulinemia: Elevated circulating insulin stimulates ovarian androgen production, which disrupts normal follicle development and prevents ovulation. This mechanism is central to PCOS-related infertility
2. LH/FSH ratio imbalance: Obesity alters the ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH), typically elevating LH relative to FSH. This pattern impairs follicular maturation and prevents the ovulatory LH surge
3. Adipose tissue estrogen: Excess fat tissue produces estrogens via the aromatase enzyme. This additional estrogen source disrupts the hypothalamic feedback signals needed to trigger ovulation
4. Leptin resistance: Obesity causes leptin resistance; leptin is a hormone the hypothalamus requires to gauge energy availability and permit reproduction. Leptin resistance effectively signals energy deficit even in the presence of excess stored energy
5. Systemic inflammation: Chronic low-grade inflammation associated with obesity suppresses reproductive function at multiple points in the HPO axis

GLP-1 medications address several of these mechanisms simultaneously. They reduce insulin resistance, lower excess androgen production, drive weight loss that decreases aromatase activity in fat tissue and improves leptin sensitivity, and exert anti-inflammatory effects. As the hormonal environment normalizes, ovulation can resume — often within weeks of starting the medication and sometimes before significant weight loss has occurred, reflecting the direct metabolic effects of GLP-1 receptor activation.

PCOS: Where the Fertility Effect Is Most Pronounced

Women with PCOS represent the population most likely to experience a meaningful fertility restoration on GLP-1 medications. PCOS is the most common cause of anovulatory infertility, and insulin resistance is central to most cases. As GLP-1 medications improve insulin sensitivity and reduce hyperinsulinemia, the cascade of androgen excess that suppresses ovulation is interrupted. Many women with PCOS who had not ovulated regularly for years begin to ovulate again — sometimes before any visible change in their cycle timing signals that this has happened.

This is the mechanism behind the 'Ozempic baby boom.' Women who had been told they had difficulty conceiving due to PCOS, who may not have been using reliable contraception because of a perceived low fertility risk, found themselves pregnant. This is an entirely predictable biological consequence of the medication's mechanism — not a pharmacological mystery, and not rare.

Oral Contraceptive Concern: The Absorption Interaction

An additional layer of complexity applies specifically to women using oral contraceptive pills. GLP-1 medications slow gastric emptying — the rate at which the stomach transfers its contents into the small intestine, where oral medications are absorbed. This slowing can reduce the peak plasma concentration (Cmax) of oral contraceptives by approximately 20–30% and delay the time to peak concentration (Tmax).

The FDA labeling for semaglutide recommends using backup contraception for at least 4 weeks when starting the medication or escalating the dose. For maximum reliability, non-oral contraceptive methods are preferred for women on GLP-1 medications:

• Non-oral methods not affected by GLP-1: hormonal IUD (Mirena, Kyleena), copper IUD, contraceptive implant (Nexplanon), transdermal patch (Xulane), vaginal ring (NuvaRing), injectable (Depo-Provera)
• If continuing oral contraceptive pills: use backup contraception for 4 weeks when starting GLP-1 or escalating the dose; take the pill at the same time every day
• Progestin-only pills require a very strict 3-hour dosing window that becomes even more difficult to maintain reliably with altered gastric motility — switching to a non-oral method is strongly recommended
• Discuss your specific contraceptive situation with your provider before starting GLP-1 therapy

Male Fertility: Testosterone and Sperm Parameters

Fertility effects are not limited to women. Men with obesity frequently experience suppressed testosterone levels through two mechanisms: aromatase in excess fat tissue converts testosterone to estrogen, reducing circulating testosterone; and excess body fat increases insulin resistance and metabolic inflammation that further impairs testicular function. Hypogonadism is significantly more prevalent in men with obesity than in those at a healthy weight.

As men lose weight on GLP-1 medications, testosterone levels commonly increase as aromatase activity decreases and metabolic health improves. Clinical studies of weight loss — from GLP-1 and other interventions — consistently show improvements in total and free testosterone with significant body weight reduction. Improved sperm parameters, including motility, morphology, and count, are also reported with meaningful weight loss in men with obesity, though the data specific to GLP-1 medications in this area is still emerging.

If You Want to Conceive: Planning Your Transition Off GLP-1

For women who do want to become pregnant, GLP-1 medications must be stopped before attempting conception. GLP-1 medications are not safe for use during pregnancy — animal studies at supratherapeutic doses showed fetal harm, and no human pregnancy safety data exists because pregnant women were excluded from all clinical trials.

The FDA recommends stopping semaglutide at least 2 months before attempting to conceive. This timeline accounts for semaglutide's half-life of approximately one week — two months of washout ensures complete drug clearance with a reasonable safety margin. Tirzepatide guidance is similar, with a recommended washout of at least one month per labeling, though many clinicians recommend two months for consistency. Confirm the exact timeline for your medication with your provider.

"The two-month washout recommendation for semaglutide before conception reflects the drug's pharmacokinetic profile and a precautionary approach in the absence of human pregnancy safety data. Women planning conception should discuss a transition plan with their provider well in advance." — Reproductive endocrinology guidance, 2025

If You Accidentally Become Pregnant on a GLP-1 Medication

Despite the risks discussed above, unexpected pregnancies do occur. If you discover you are pregnant while taking a GLP-1 medication, the steps are clear:

1. Stop the medication immediately — do not take another dose
2. Contact your obstetrician or healthcare provider as soon as possible
3. Inform your provider that you were taking a GLP-1 medication and how recently your last dose was
4. Understand that no confirmed cases of GLP-1-related human fetal harm have been documented from accidental early exposures; the concern is precautionary based on animal data at high doses
5. Your OB may recommend additional monitoring during early pregnancy; most will reassure you that a brief early exposure is unlikely to cause harm, though formal safety data is limited
6. Report the pregnancy to the manufacturer's pregnancy registry — this data is critical for building the safety evidence base

After Baby: Restarting GLP-1 Postpartum

Many women want to restart GLP-1 medications after delivery. The timing depends primarily on breastfeeding status:

• If not breastfeeding: GLP-1 medications can typically be restarted after delivery — most providers recommend waiting 6–8 weeks postpartum pending recovery assessment
• If breastfeeding: GLP-1 medications are not recommended during lactation. It is unknown whether meaningful drug levels pass into breast milk or what effects they might have on a nursing infant
• After weaning: Once breastfeeding is completed, restarting GLP-1 therapy is appropriate with provider guidance on timing and dosing

Key Takeaways for Reproductive Planning

• GLP-1 medications may restore fertility — especially in women with PCOS or obesity-related anovulation
• Oral contraceptives may have reduced reliability due to slowed gastric emptying; non-oral methods are preferred
• GLP-1 medications must be stopped at least 2 months before planned conception (semaglutide); confirm timing for your specific drug
• If accidentally pregnant, stop immediately and contact your provider
• Men may experience testosterone restoration and improved sperm parameters with GLP-1-driven weight loss
• Discuss reproductive planning as part of every GLP-1 medication counseling conversation

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.